TMEM158, as plasma cfRNA marker, promotes proliferation and doxorubicin resistance in ovarian cancer [0.03%]
TMEM158作为血浆cfRNA标记物促进卵巢癌细胞的增殖和多柔比星耐药性
Xiaolin Zhu,Tongchao Liu,Xuexue Yin
Xiaolin Zhu
The current study aimed to identify the potential biomarker for the diagnosis of ovarian cancer within plasma cell-free RNA (cfRNA) species and to characterize their oncogenic properties. cfRNAs were isolated from the peripheral blood of ov...
The ZNF263/CPT1B axis regulates fatty acid β-oxidation to affect cisplatin resistance in lung adenocarcinoma [0.03%]
锌指抗凋亡基因ZNF263通过CPT1B调节肺癌脂肪酸氧化以影响顺铂耐药性
Renhe Yan,Caibin Zheng,Suting Qian et al.
Renhe Yan et al.
Cisplatin is widely used as a conventional chemotherapy drug for lung adenocarcinoma (LUAD) patients. However, the chemical resistance greatly limits its therapeutic potential. The study aimed to uncover the specific role and new mechanisms...
Cost analysis of CYP2C19 genetic testing in percutaneous coronary intervention patients [0.03%]
冠脉介入患者中CYP2C19基因检测的成本分析
Samuel Huxley,James Moriarty,Mark A Hlatky et al.
Samuel Huxley et al.
CYP2C19 loss of function (LOF) carriers undergoing percutaneous coronary intervention (PCI) have an increased risk of ischemic events when treated with clopidogrel. PCI patients in TAILOR-PCI were randomized to clopidogrel or genotype-guide...
Randomized Controlled Trial
The pharmacogenomics journal. 2024 Oct 8;24(6):32. DOI:10.1038/s41397-024-00353-y 2024
Effects and interaction of single nucleotide polymorphisms at the pharmacokinetic/pharmacodynamic site: insights from the Rotterdam study into metformin clinical response and dose titration [0.03%]
药动/药效学位点单核苷酸多态性的效应和交互作用：来自鹿特丹研究中二甲双胍临床反应及剂量调整的启示
Soroush Mohammadi Jouabadi,Payam Peymani,Mitra Nekouei Shahraki et al.
Soroush Mohammadi Jouabadi et al.
Our study investigated the impact of genetic variations on metformin glycemic response in a cohort from the Rotterdam Study, comprising 14,926 individuals followed for up to 27 years. Among 1285 metformin users of European ancestry, using l...
Clinical and economic outcomes of a pharmacogenomics-enriched comprehensive medication management program in a self-insured employee population [0.03%]
基于药物基因组学的综合用药管理项目的临床和经济效益分析——INSIGHT研究
Maren S Fragala,Murray Keogh,Steven E Goldberg et al.
Maren S Fragala et al.
Clinical and economic outcomes from a pharmacogenomics-enriched comprehensive medication management program were evaluated over 26 months in a self-insured U.S. employee population (n = 452 participants; n = 1500 controls) using propensity ...
Extreme phenotype sampling and next generation sequencing to identify genetic variants associated with tacrolimus in African American kidney transplant recipients [0.03%]
极端表型取样和下一代测序技术在识别非洲裔美国人肾移植受者他克莫司相关遗传变异中的应用
Moataz E Mohamed,Bin Guo,Baolin Wu et al.
Moataz E Mohamed et al.
African American (AA) kidney transplant recipients (KTRs) have poor outcomes, which may in-part be due to tacrolimus (TAC) sub-optimal immunosuppression. We previously determined the common genetic regulators of TAC pharmacokinetics in AAs ...
Christine M Formea,Paldeep Atwal,Kathryn Meintsma et al.
Christine M Formea et al.
A collaborative force for precision medicine progress: the STRIPE pharmacogenomics conference series [0.03%]
精准医疗进展的协作力量：STRIPE药物基因组学大会系列
Sara L Rogers,J Shawn Jones,Ben L Kong et al.
Sara L Rogers et al.
Ben L Kong,Roseann S Donnelly,Amina Abubakar et al.
Ben L Kong et al.
Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment [0.03%]
理解初级保健中全科医生和药剂师对药物基因组检测偏好的实验研究：一种离散选择实验的方法
John H McDermott,Videha Sharma,Glenda M Beaman et al.
John H McDermott et al.
Pharmacogenetic testing in the United Kingdom's National Health Service (NHS) has historically been reactive in nature, undertaken in the context of single gene-drug relationships in specialist settings. Using a discrete choice experiment w...